Statins and angiogenesis: Is it about connections?

Biochemical and Biophysical Research Communications

Volumn 387, Issue 3, 2009, Pages 543-547

  Khaidakov, Magomed ^a   Wang, Wenze ^a   Khan, Junaid A ^a   Kang, Bum Yong ^a   Hermonat, Paul L ^a   Mehta, Jawahar L ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Angiogenesis; Junction proteins; Statins; VE cadherin

Indexed keywords

ANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIGEL; ROSUVASTATIN; SIMVASTATIN; VASCULAR ENDOTHELIAL CADHERIN;

ANGIOGENESIS; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; ENDOTHELIUM CELL; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; THORACIC AORTA; UMBILICAL VEIN;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD; AORTA; CADHERINS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PYRIMIDINES; SIMVASTATIN; SULFONAMIDES; UMBILICAL VEINS;

EID: 68249097560     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.07.057     Document Type: Article

References (29)

1. Kapur N.K., and Musunuru K. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc. Health Risk Manag. 4 (2008) 341-353
2. Liao J.K., and Laufs U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 45 (2004) 89-118
3. Zhou Q., and Liao J.K. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr. Pharm. Des. 15 (2009) 467-478
4. Wong W.W., Dimitroulakos J., Minden M.D., and Penn L.Z. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16 (2002) 508-519
5. John S., Delles C., Jacobi J., Schlaich M.P., Schneider M., Schmitz G., and Schmieder R.E. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J. Am. Coll. Cardiol. 37 (2001) 1351-1358
6. Chen J., Li D., Schaefer R.F., and Mehta J.L. Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis. J. Cardiovasc. Pharmacol. 44 (2004) 446-452
7. Mehta J.L., Li D.Y., Chen H.J., Joseph J., and Romeo F. Inhibition of LOX-1 by statins may relate to upregulation of eNOS. Biochem. Biophys. Res. Commun. 289 (2001) 857-861
8. Versteilen A.M.G., Korstjens I.J.M., Musters R.J.P., Groeneveld A.B.J., and Sipkema P. Rho kinase regulates renal blood flow by modulating eNOS activity in ischemia-reperfusion of the rat kidney. Am. J. Physiol. Renal Physiol. 291 (2006) F606-F611
9. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D.J., Sessa W.C., and Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6 (2000) 1004-1010
10. Karthikeyan V.J., and Lip G.Y. Statins and intra-plaque angiogenesis in carotid artery disease. Atherosclerosis 192 (2007) 455-456
11. Poynter J.N., Gruber S.B., and Higgins P.D. Statins and the risk of colorectal cancer. N. Engl. J. Med. 352 (2005) 2184-2192
12. Friis S., Poulsen A.H., and Johnsen S.P. Cancer risk among statin users: a population-based cohort study. Int. J. Cancer 114 (2005) 643-647
13. Dulak J., and Józkowicz A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr. Cancer Drug Targets 5 (2005) 579-594
14. Weis M., Heeschen C., Glassford A.J., and Cooke J.P. Statins have biphasic effects on angiogenesis. Circulation 105 (2002) 739-745
15. Tsai C.H., Yeh H.I., Tian T.Y., Lee Y.N., Lu C.S., and Ko Y.S. Down-regulating effect of nicotine on connexin43 gap junctions in human umbilical vein endothelial cells is attenuated by statins. Eur. J. Cell Biol. 82 (2004) 589-595
16. Martin T.A., Mansel R., and Jiang W.G. Hepatocyte growth factor modulates vascular endothelial-cadherin expression in human endothelial cells. Clin. Cancer Res. 7 (2001) 734-737
17. Caveda L., Martin-Padura I., Navarro P., Breviario F., Corada M., Gulino D., Lampugnani M.G., and Dejana E. Inhibition of cultured cell growth by vascular endothelial cadherin (cadherin-5/VE-cadherin). J. Clin. Invest. 98 (1996) 886-893
18. Vestweber D., Winderlich M., Cagna G., and Nottebaum A.F. Cell adhesion dynamics at endothelial junctions: VE-cadherin as a major player. Trends Cell Biol. 19 (2009) 8-15
19. Gory-Fauré S., Prandini M.H., Pointu H., Roullot V., Pignot-Paintrand I., Vernet M., and Huber P. Role of vascular endothelial-cadherin in vascular morphogenesis. Development 126 (1999) 2093-2102
20. Gotsch U., Borges E., Bosse R., Böggemeyer E., Simon M., Mossmann H., and Vestweber D. VE-cadherin antibody accelerates neutrophil recruitment in vivo. J. Cell Sci. 110 (1997) 583-588
21. Matsuyoshi N., Toda K., Horiguchi Y., Tanaka T., Nakagawa S., Takeichi M., and Imamura S. In vivo evidence of the critical role of cadherin-5 in murine vascular integrity. Proc. Assoc. Am. Physicians 109 (1997) 362-371
22. Romano M., Diomede L., Sironi M., Massimiliano L., Sottocorno M., Polentarutti N., Guglielmotti A., Albani D., Bruno A., Fruscella P., Salmona M., Vecchi A., Pinza M., and Mantovani A. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab. Invest. 80 (2000) 1095-1100
23. Rezaie-Majd A., Prager G.W., Bucek R.A., Schernthaner G.H., Maca T., Kress H.-G., Valent P., Binder B.R., Minar E., and Baghestanian M. Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 397
24. Lampugnani M.G., Zanetti A., Breviario F., Balconi G., Orsenigo F., Corada M., Spagnuolo R., Betson M., Braga V., and Dejana E. VE-cadherin regulates endothelial actin activating Rac and increasing membrane association of Tiam. Mol. Biol. Cell 13 (2002) 1175-1189
25. Nelson C.M., Pirone D.M., Tan J.L., and Chen C.S. Vascular endothelial-cadherin regulates cytoskeletal tension, cell spreading, and focal adhesions by stimulating RhoA. Mol. Biol. Cell 15 (2004) 2943-2953
26. Wallez Y., and Huber H. Endothelial adherens and tight junctions in vascular homeostasis, inflammation and angiogenesis. Biochim. Biophys. Acta 1778 (2008) 794-809
27. Koutouzis M., Nomikos A., Nikolidakis S., Tzavara V., Andrikopoulos V., Nikolaou N., Barbatis C., and Kyriakides Z.S. Statin treated patients have reduced intraplaque angiogenesis in carotid endarterectomy specimens. Atherosclerosis 192 (2007) 457-463
28. Graaf M.R., Richel D.J., van Noorden C.J., and Guchelaar H.J. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat. Rev. 30 (2004) 609-641
29. Corada M., Zanetta L., Orsenigo F., Breviario F., Lampugnani M.G., Bernasconi S., Liao F., Hicklin D.J., Bohlen P., and Dejana E. A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood 100 (2002) 905-911